Drug Trial Radar · NCT05937490
Adenomyosis and ART
Last checked: Nov 20, 2026Latest source record: Jul 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 27, 2023
Primary completion
Mar 2025
Study completion Mar 2025
Sponsor
- Lead sponsor
- Azienda Ospedaliero-Universitaria di ModenaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Modena and Reggio Emilia; Ministero della Salute, Italy
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 42 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to: * Prospectively investigate the association of Adenomyosis with fertility outcomes in relation to COH protocols for ART (long or ultra- long protocol) with a preventive high-dose anti-inflammatory progestin such as DNG and to assess their association with pregnancy and neonatal outcomes (preterm delivery,pre-eclampsia,Caesarean section,fetal malpresentation,small for gestational age,low birth weight and postpartum hemorrhage). * Understand how the endometrial interface by studying the response of progesterone and DNG stimulated decidualization markers, correlating them with the success of ART protocol stimulation and to pregnancy specific outcomes * Evaluate the immune changes during the implantation period and in the different trimesters of the pregnancies after ART conception.
Conditions
- Adenomyosis
Interventions
EnantoneDrug
administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
Dienogest 2 MG (milligram)Drug
Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
EnantoneDrug
COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
long GnRH agonist or flexible GnRH antagonist protocol.Drug
During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- live birth after ARTTime frame: Through study completion, an average of 2 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Azienda Ospedaliero-Universitaria di Modena
Modena, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.